Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2015 - 2023)
Spyre Therapeutics (SYRE) posted Depreciation & Amortization (CF) of $360000.0 for Q2 2023, down 6.25% on a QoQ basis from $384000.0 in Q1 2023, and down 4.76% year-over-year from $378000.0 in Q2 2022.
Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2015 - 2023) Analysis & Trends
Spyre Therapeutics' Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $360000.0 for Q2 2023.
- Quarterly Depreciation & Amortization (CF) fell 4.76% year-over-year to $360000.0 in Q2 2023, while the trailing twelve-month figure through Mar 2024 was $360000.0 (down 76.74% YoY) and the FY2023 annual result came in at $744000.0, down 52.52% from the prior year.
- Depreciation & Amortization (CF) was $360000.0 for Q2 2023 at Spyre Therapeutics, down from $384000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $412000.0 in Q3 2021 and bottomed at $100000.0 in Q1 2019.
- A 5-year average of $294500.0 and a median of $364500.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2020 — Depreciation & Amortization (CF) soared 248.11% — and 2022, when it fell 6.33%.
- Spyre Therapeutics' Depreciation & Amortization (CF) stood at $106000.0 in 2019, then surged by 248.11% to $369000.0 in 2020, then climbed by 11.38% to $411000.0 in 2021, then decreased by 6.33% to $385000.0 in 2022, then decreased by 6.49% to $360000.0 in 2023.
- Business Quant data shows SYRE's Depreciation & Amortization (CF) at $360000.0 in Q2 2023, $384000.0 in Q1 2023, and $385000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 360,000.00 |
| Jun 30, 2023 | 360,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Mar 31, 2023 | 384,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Dec 31, 2022 | 385,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Sep 30, 2022 | 401,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Jun 30, 2022 | 378,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Mar 31, 2022 | 403,000.00 |
| Dec 31, 2021 | 411,000.00 |
| Dec 31, 2021 | 411,000.00 |
| Sep 30, 2021 | 412,000.00 |
| Sep 30, 2021 | 412,000.00 |
| Jun 30, 2021 | 398,000.00 |
| Jun 30, 2021 | 398,000.00 |
| Mar 31, 2021 | 355,000.00 |
| Mar 31, 2021 | 355,000.00 |